Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Specialty — Operating loss

Similar metrics at other companies

Marcus Corporation logo
MCSTheatres — Operating loss
$26.66M+69.8%
LiveWire Group logo
LVWRSTACYC — Operating loss
$26K+110%
Marcus Corporation logo
MCSHotels/Resorts — Operating loss
$6.7M+59.8%
Cipher Digital, Inc. logo
CIFRBitcoin Mining — Operating loss
-$114.57M-201%
LiveWire Group logo
LVWRElectric Motorcycles — Operating loss
-$18.04M-0.2%
Applied Digital logo
APLDCloud Services Business — Operating loss
-$52.19M-406%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.79B+113%
Enterprise value$8.24B+70.5%
P/E36.8×-768×
P/S1.9×+0.9×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-K, filed February 27, 2026.

Filed
Feb 26, 2026, 7:00 PM EST
Fiscal year
FY2025
Accession
0001723128-26-000011
Line itemYears Ended December 31, 2025Years Ended December 31, 2024Years Ended December 31, 2023
Restructuring and other charges4,2082,3551,749
(Credit) charges related to legal matters, net(390)96,6921,824
Other operating income(5,240)(930)(15,635)
Operating income394,096249,326204,374
Other (expense) income:
Interest expense, net(241,091)(258,595)(210,629)
Foreign exchange gain (loss), net7,635(6,846)1,671
Loss on refinancing(31,365)(40,805)

Item 16. Form 10-K Summary

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — operating loss?
Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — operating loss of $29M in Q4 2025.
How has Amneal Pharmaceuticals, Inc.'s specialty — operating loss changed year-over-year?
Amneal Pharmaceuticals, Inc.'s specialty — operating loss increased by 2.1% year-over-year, from $28.4M to $29M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — operating loss?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — operating loss has grown at a 19.7% compound annual growth rate (CAGR), from $56.42M to $116M.
What does specialty — operating loss mean?
Indicates the extent to which a business segment's operating expenses exceed its gross revenue. A persistent operating loss suggests that the segment is not yet self-sustaining or is facing significant competitive or cost pressures.

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — operating loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude